Please use one of the following formats to cite this article in your essay, paper or report: APA. Sphere Bio. (2025, May 21). The best practices to enhance cell line development.

The cost of plasmids and transfection reagent comprises roughly 40% of the total cost to manufacture AAV without a producer cell line. Eliminating these expensive components has the potential to ...

However, even some [production] cell lines need enhanced transfection conditions. Cells relevant for cell therapeutic approaches, usually blood or stem cells, are notoriously hard to transfect.

Over the past few years, Kyfora Bio has developed a line of research-grade (PEI MAX™ and Transporter 5™) and GMP-grade (MAXgene™ GMP) PEI transfection reagents suitable for seamless transitions from ...

Polyplus-transfection(R) SA, the leading biotechnology company that supports gene and cell therapy by supplying innovative transfection solutions, today announces the availability of the first GMP ...

STEMCELL Technologies has commercially launched the CellPore™ Transfection System, providing a groundbreaking new technology with the potential to advance cell engineering research and the ...

During cell therapy development, some scientists are moving away from viral transfection and toward electroporation for introducing CRISPR systems and other nucleic acid payloads. As electroporation ...